Towards Healthcare
Fondaparinux Market to Lead USD 1419.61 Mn by 2035

Fondaparinux Market Booming with Global Anticoagulant Needs

Based on market forecasts, the global fondaparinux market, projected at USD 721 million in 2025, is expected to reach USD 1419.61 million by 2035, growing at a CAGR of 6.36% over the forecast period. The increasing number of surgeries and growing research activities drive the global market. North America dominated the global market owing to the presence of key players and a robust healthcare infrastructure.

Content

  • Last Updated: 04 November 2025
  • Report Covered: [Revenue + Volume]
  • Historical Year: 2021-2023
  • Base Year: 2024
  • Estimated Years: 2025-2034

About The Author

Shivani Zoting is a dedicated research analyst specializing in the healthcare industry. With a strong academic foundation, a B.Sc. in Biotechnology and an MBA in Pharmabiotechnology, she brings a unique blend of scientific understanding and market strategy to her research.

Shivani contributes to Towards Healthcare and plays an active role at Precedence Research, where she focuses on delivering in-depth market intelligence, competitive analysis, and trend forecasting across pharmaceuticals, medical devices, digital health, and healthcare services. Her insights support healthcare companies, investors, and policymakers in making data-backed decisions in a highly regulated and rapidly evolving sector.

Additionally, Shivani collaborates with Statifacts, further expanding her healthcare domain reach by engaging in diverse projects across global markets. Her strength lies in transforming complex clinical and commercial data into strategic narratives that help stakeholders navigate the future of healthcare.

Talk to us
FAQ's

The fondaparinux market holds a valuation of USD 815.56 million as of 2026, and will expand to USD 1419.61 million by 2035, achieving a CAGR of 6.36% between 2026 and 2035.

North America is leading the fondaparinux market share by 42% due to the availability of state-of-the-art research and development facilities, a robust healthcare infrastructure, and the increasing adoption of advanced technologies.

Some key players include GlaxoSmithKline, Bayer, and Abbott Laboratories.

Key trends include the rising prevalence of chronic disorders, the availability of generic alternatives, and growing research activities.

Fondaparinux is found to be efficacious in the prevention of deep vein thrombosis (DVT) compared to heparins. Some studies have also found that fondaparinux could reduce major bleeding events and improve survival compared to low-molecular-weight heparin.

American Joint Replacement Registry, Centers for Disease Control and Prevention, CMS.gov, clinicaltrials.gov, English.cn.gov
Any Questions